Buspirone, a 5-hydroxytryptamine1A agonist, is active in cerebellar ataxia. Results of a double-blind drug placebo study in patients with cerebellar cortical atrophy

Archives of Neurology
P TrouillasB Laurent

Abstract

To establish the antiataxic effect of buspirone hydrochloride, a serotonergic 5-hydroxytryptamine1A (5-HT1A) agonist, in a homogenous group of patients characterized by the same well-defined single condition, cerebellar cortical atrophy. University ataxia research center. Double-blind randomized study of buspirone vs placebo during a 4-month period. Nineteen patients met the inclusion criteria; all completed the study. Of these 19 patients, 9 were treated with placebo and 10 were treated with the drug. A semiquantitative scale for kinetic and static ("postural") cerebellar functions; quantitative clinical measurements measuring time in standard tests that evaluated stance, speech, writing, and drawing; and posturographic analysis of the sway path and sway area of the center-of-foot pressure. The primary end point was improvement of the posttherapeutic change of one of the semiquantitative ataxic scores. The secondary end points were modification of the changes of quantitative measures--clinical or posturographic. In intention-to-treat analysis, a significant improvement of the primary end point, ie, the posttherapeutic change of the ataxic kinetic score, was shown. Among secondary end points, the maximum time of standing with f...Continue Reading

Citations

Oct 23, 2013·Pflügers Archiv : European journal of physiology·Chang-Zheng ZhangJian-Jun Wang
Jun 17, 2000·European Journal of Pharmacology·T A ReaderR Lalonde
Jun 27, 2002·Journal of Chemical Neuroanatomy·Frederik J GeurtsJean-Pierre Timmermans
Nov 30, 2000·Current Treatment Options in Neurology·S L Perlman
Dec 9, 2004·Experimental Brain Research·D TimmannF P Kolb
Aug 10, 2005·Pediatric Neurology·Ryan J Felling, Todd F Barron
Jan 29, 2008·Journal of the Neurological Sciences·José Gazulla, Pedro Modrego
Nov 25, 2003·Psychiatry and Clinical Neurosciences·Asako TakeiKunio Tashiro
Apr 16, 2002·Psychiatry and Clinical Neurosciences·Asako TakeiKunio Tashiro
Oct 29, 2014·The Cochrane Database of Systematic Reviews·Adam P VogelMatthew L Poole
Sep 9, 2005·The Cerebellum·Asako TakeiHidenao Sasaki
Jun 12, 2014·Movement Disorders Clinical Practice·Harini Sarva, Vicki Lynn Shanker
Jun 29, 2006·Neurochemical Research·Robert Lalonde, Catherine Strazielle
Aug 18, 2001·Pharmacology, Biochemistry, and Behavior·N Le MarecR Lalonde

❮ Previous
Next ❯

Related Concepts

Related Feeds

Ataxia telangiectasia (MDS)

Ataxia telangiectasia is a rare neurodegenerative diseases caused by defects in the ATM gene, which is involved in DNA damage recognition and repair pathways. Here is the latest research on this autosomal recessive disease.

Ataxias

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on different types of ataxias here.